Rapid Clinical Updates: From Failure to Function: Closing the Gap Between Heart Failure Guidelines and Bedside Care-Handout

Pdf Summary

This document summarizes rapid clinical updates for inpatient and discharge management of heart failure.

For <strong>HFrEF</strong>, the key message is that hospitalization is the best opportunity to start and optimize guideline-directed medical therapy (GDMT). Patients should leave the hospital on low doses of all four foundational therapies when possible: <strong>ACEi/ARB/ARNI, beta-blocker, mineralocorticoid receptor antagonist (MRA), and SGLT2 inhibitor</strong>. If tolerated, medications should be titrated to at least 50% of target dose before discharge, with close follow-up at 1, 2, 3, and 6 weeks. Reaching target doses by 6 weeks is associated with substantial reductions in mortality and HF readmissions. Practical thresholds are given for holding or adjusting therapy: ARNI/ACEi caution with low systolic BP, hyperkalemia, or renal decline; beta-blockers should be started once euvolemic and off IV inotropes; MRA use requires acceptable potassium and kidney function. Vericiguat may be added for persistent hospitalizations despite GDMT, and ICD decisions should wait until EF is reassessed after 90 days of optimized therapy.

For <strong>HFpEF/HFmrEF</strong>, treatment focuses on blood pressure control, comorbidity management, and obesity. Newer options include <strong>finerenone</strong> and <strong>GLP-1 receptor agonists</strong> in selected patients, especially those with diabetes, CKD, or obesity. The document also emphasizes recognizing <strong>amyloidosis</strong> in patients with HFpEF and suggestive features such as LVH without severe hypertension, carpal tunnel syndrome, lumbar stenosis, autonomic symptoms, or low-normal BP.

For <strong>all EF categories</strong>, <strong>SGLT2 inhibitors</strong> are recommended inpatient and regardless of diabetes status, with counseling about euglycemic DKA and holding the drug during fasting or surgical stress.

For <strong>in-hospital diuresis</strong>, higher loop diuretic doses often improve fluid removal, and adding <strong>acetazolamide or thiazides</strong> can enhance decongestion. Finally, safe transition out of the hospital requires early follow-up, lab checks, and weight monitoring.

Meta Tag

Concept Heart Failure with Reduced Ejection Fraction

Concept Guideline-Directed Medical Therapy

Concept Heart Failure with Preserved Ejection Fraction

Concept Heart Failure with Mildly Reduced Ejection Fraction

Concept ACE Inhibitor

Keywords

heart failure

HFrEF

HFpEF

HFmrEF

guideline-directed medical therapy

SGLT2 inhibitors

hospital discharge

diuresis

amyloidosis

vericiguat

Heart Failure with Reduced Ejection Fraction

Guideline-Directed Medical Therapy

Heart Failure with Preserved Ejection Fraction

Heart Failure with Mildly Reduced Ejection Fraction

ACE Inhibitor